BooDog BULLISH $IBIO For some I'm sure IBIO hasn't been the best play. Maybe I see something others don't. Like $3 to $5 potential. This puppy hasn't failed me yet.
“Although we are pleased to have executed on our November promise to build a high-value oncology portfolio, we are even more pleased to deliver results in other areas of our Biopharmaceutical segment, especially our next-generation COVID-19 vaccine, IBIO-202. We believe that there is a critical need to design new vaccines that can target regions of the virus aside from the frequently mutating spike protein, in order to address the looming risk of an escape variant. IBIO-202 could potentially represent one such option, given that it targets the more highly conserved nucleocapsid protein of SARS-CoV-2, and in preclinical models of disease, drove robust memory T cell responses. We look forward to updating investors on IBIO-202 after we receive feedback on our pre-IND package, which was submitted earlier this month.”
Based on current plans, iBio believes the current cash position is sufficient to fund operations through the first calendar quarter of 2023.
